Skip to main content
Free trial

Ask AI to review this stock

Copy the prompt to get recent events, historical reactions, and a short research brief.

Tell your AI:

Help me set up FinLab and analyze 6612 奈米醫材. Please read: https://finlab.finance/en/setup?stock=6612

No install, open FinLab Studio

6612

奈米醫材 Biotech & Healthcare As of 2026-06-17 Updated daily after market close

steady quality, premium valuation.

1 active signal
Revenue ≥20%
This page refreshes daily after the close. Add 奈米醫材 to your watchlist to track signal changes on your next visit.
Valuation 38Quality 55Growth 82Momentum 27Chips 5

Is 奈米醫材 a buy? Fundamentals and valuation first

  • Above-average profitability.Operating margin is in the 68th market percentile. Latest quarterly ROE ≈ 1.2%.

  • Valuation is high.PE is in the 86th market percentile; within its own history, PE is around the 96th percentile.

  • Foreign investors are net selling.Foreign 20-day net flow ≈ -8.1% of volume (net sell).

  • Strong revenue growth.Latest monthly revenue YoY ≈ 43.3%, above the 20% growth threshold.

  • Signals are active now.On the latest data, signals such as Revenue YoY ≥ 20% are active — see the historical forward returns after each occurrence below.

Chip flow

Bullish +0.47
BearishNeutralBullish

Single-sided accumulation, concentration rising — bullish

  • Single-sided accumulation, concentration rising — bullish
  • 兆豐-新竹 holds 268 lots
  • sellers have 33 lots left, ~60 sessions to clear

Window from 2026-01-17 · Price -14% · branches to 2026-06-17· TDCC to 2026-06-12

  • Largest holder 兆豐-新竹 has accumulated 268 lots since the start (sold 0%), still adding.
  • Main distributor 港商野村 peaked at 28 lots, has sold 57%, 12 left, paused recently.
  • TDCC big holders (absolute) >1000-lot holders +0.53pp, mid holders +0, retail -0.23pp — concentration shifting upward.
  • Foreign hedge-desk net short Net short -66 lots (inferred from branch profile, mostly hedging — not necessarily bearish, not case-confirmed).
Branch inventory reconstruction
Accumulating holders Branches that accumulated shares during the window and still hold positive inventory; they are the absorbing side.
Distributing sellers Branches that built inventory earlier and have been selling it down; the remaining number estimates what has not cleared.
Net-short desks Trading-desk branches with negative inventory or net selling, often hedge, offsetting, or short-term flow. It is not automatically a bearish view.
Accumulating
兆豐-新竹永豐金-竹北台新證券元大-台北兆豐-台中港元大-大益
Distributing
港商野村永豐金-板新凱基-基隆華南永昌元大-豐原凱基-新豐
Desks
own scale
統一-桃園統一-中壢第一金-台南凱基-台北
Price Accumulating & Distributing share one scale (comparable); Desks is independent. Zero is the baseline
Branch details Unit: lots

Accumulating

  • 兆豐-新竹 +268
    sold 0%· still adding
  • 永豐金-竹北 +199
    sold 0%· still adding
  • 台新證券 +109
    sold 0%
  • 元大-台北 +47
    sold 0%
  • 兆豐-台中港 +40
    sold 0%· still adding
  • 元大-大益 +39
    sold 0%· still adding

Distributing

  • 港商野村 12 left
    sold 57%· paused recently
  • 永豐金-板新 12 left
    sold 25%· ~60 sessions to clear
  • 凱基-基隆 8 left
    sold 33%· ~27 sessions to clear
  • 華南永昌 7 left
    sold 30%· paused recently
  • 元大-豐原 2 left
    sold 80%· paused recently
  • 凱基-新豐 4 left
    sold 60%· paused recently

Desks

  • 統一-桃園 -179
    unclassified
  • 統一-中壢 -143
    unclassified
  • 第一金-台南 -114
    unclassified
  • 凱基-台北 -65
    day-trade · selling pressure
Still selling 33 lots ~60 sessions to bottom at most
Recent buy/sell force +211 absorbed / -18 sold buyers slightly ahead
TDCC big holders · absolute-holding cross-check
>1000-lot holder share Retail (<400 lots) share Price (right axis)

Direction matches: big-holder share rose while retail share fell.

Describes chip flow, not investment advice. Branch data discloses only high-volume branches with ~1-day lag; TDCC is weekly. Inventory is a relative reconstruction from the window start, not absolute holdings.

Historical evidence

Signals active now

These signals are true on the latest data, with this stock's own historical forward-return stats after each occurrence.

Monthly revenue YoY ≥ 20% (from filing deadline)

Active · now 43.3%

Monthly revenue YoY ≥ 20%; event date is the first trading day after the filing deadline (no look-ahead).

56 historical occurrences (since 2018-07-18)
Average forward return after Monthly revenue YoY ≥ 20% (from filing deadline)。20-day: Win 44.7%, Sample 47, Median -0.85%, Excess +1.31%, Beat mkt rate 42.6%；60-day: Win 48.9%, Sample 47, Median -0.16%, Excess +0.5%, Beat mkt rate 44.7%；120-day: Win 50%, Sample 46, Median -0.09%, Excess -1.21%, Beat mkt rate 43.5%

120 days after: historical avg +4.39%

20-day +1.33%
60-day +2.43%
120-day +4.39%
20-day
60-day
120-day
Win
44.7%
48.9%
50%
Sample
47
47
46
Median
-0.85%
-0.16%
-0.09%
Excess
+1.31%
+0.5%
-1.21%
Beat mkt rate
42.6%
44.7%
43.5%

Over 46 occurrences, 120-day forward avg gained 4.39%, lagged the market by 1.21 pts; win rate 50%.

Valuation regime and subsequent returns

Each day's PE is converted to its own-history percentile (as of that day), then we look at adjusted-close returns over the next 240 trading days by valuation regime.

PE percentile bandSample days240-day avg returnMedianWin rateAvg excess (vs index)
0-20 100+62.2% +60.8% 100% +38.4%
20-40 117+65.5% +59% 99.1% +43.8%
40-60 153+10.6% +11.5% 70.6% -23.2%
60-80 204-0.3% -15.4% 34.8% -42.9%
80-100 You are here363+1.8% -12.6% 44.4% -4.5%

Percentiles use an expanding own-history window (no look-ahead); forward return is 240 trading days on adjusted close. Sample days overlap; distribution is indicative only.

Current PE ≈ 81.69, at the 96.3th percentile of its own history (80-100 band).

Valuation × momentum historical grid

Every day in its own history is bucketed by valuation tercile (own-history PE) and 60-day momentum sign into six cells; we show adjusted-close returns over the next 120 trading days per cell.

Valuation
Momentum
Cheap (own-history bottom 1/3)
Mid
Expensive (own-history top 1/3)
60-day momentum up
+79.2%
Win rate 100% Excess +65.7%
64d
-3.3%
Win rate 52.5% Excess -17.5%
120d
Now
-4.8%
Win rate 34.6% Excess -5%
306d
60-day momentum down
+77.6%
Win rate 100% Excess +62.7%
71d
-1.2%
Win rate 39.8% Excess -24.3%
236d
+2.3%
Win rate 40.2% Excess -9%
259d

Currently in “Expensive (own-history top 1/3) × 60-day momentum up”: across 306 historical days, 120-day forward avg declined 4.8%, win rate 34.6%, lagged the market by 5%.

Days = trading days in this bucket; returns use adjusted prices, ex-costs. 60-day momentum: direction of this stock's price over the past 60 trading days.

Does this signal hold up across the market

Over the past 242 months, on average ~404 stocks per month met “monthly revenue YoY ≥ 20%”; their adjusted-close return over the next 60 trading days averaged 6.94% (equal-weighted), beating the market by 2.37 points on average, and outperformed the TAIEX total-return index in 64.5% of months.

Each month, equal-weighted 60-day forward adjusted return of all signal-matching stocks, then averaged across months; excess vs the TAIEX total-return index.

Signals not active (historical stats for reference)

These are not occurring now; historical samples shown for comparison.

252-day price high (breakout)

Pending

Adjusted close makes a new 252-day high; repeats within 20 days counted once.

7 times historically; 60-day forward avg +15.92%, win rate 71.4%, beating the market by +15.26 pts on average.

Foreign net buying for 5 straight days

Pending

Foreign net flow (ex-dealer) positive for 5 straight days; event on day 5; repeats within 20 days counted once.

23 times historically; 60-day forward avg +4.58%, win rate 56.5%, beating the market by +0.08 pts on average.

What does 奈米醫材 do? Company profile

生技醫療業；眼科醫療器材、人工水晶體、人工水晶體植入系統、植入／侵入式高階醫材表面處理 上櫃（櫃買中心 TPEx）

Overview

應用奈米醫材科技股份有限公司成立於2011年7月14日，總部與公司地址位於新竹縣竹北市生醫路2段16號4樓，2018年7月18日於櫃買中心上櫃，證券代號6612，屬普通股。董事長為樂亦宏，總經理為陳秉淳，發言人為陳丹荔。鉅亨網公司資料顯示資本額約新台幣4.75億元、已發行股數約4,751.46萬股；公司2025年度合併財報顯示2025年底普通股股本為新台幣475,146千元，2026年第1季仍為475,146千元。主要股東依公司2026年股東會主要股東名單，截至2026年3月29日包括LOH TRUST HOLDINGS LLC持股15.39%、樂亦宏（LOH, IH-HOUNG）持股11.59%、WILLIAM LEE持股4.65%、三陽金屬工業股份有限公司持股4.08%、W TSENG HOLDINGS LLC持股3.56%、宗原國際股份有限公司持股3.27%、碩億投資股份有限公司持股2.34%、莊美霞持股2.00%、蘇文雄持股1.99%、張維仁持股1.90%。員工規模方面，2025年法說摘要來源指出截至2025年6月30日集團員工約406人；此數字非公司財報主表直接揭露，採中等信心引用。主要子公司與投資包括美國AST Products, Inc.（植／侵入式高階醫材表面處理技術）、美國AST VisionCare Inc.（眼科醫療器械經銷）、香港ICARES MEDICUS (HONG KONG) LIMITED、台灣詠豪科技股份有限公司（醫材及電子塑膠製品射出成型、模具設計開發與生產，持股60%）、美國Millennium Biomedical, Inc.（MBI，白內障手術用人工水晶體產品；集團透過AST VisionCare於2024年收購主要股權）、大陸碩創（上海）醫療器械有限公司（人工水晶體產品研發、生產）。

Business

公司為營運公司，核心業務是白內障手術用人工水晶體（IOL）、人工水晶體植入系統（IOL delivery system）、醫材表面潤滑塗層／表面處理技術授權與服務，以及併入詠豪科技後的醫材及電子塑膠製品射出成型與模具業務。主要產品與服務可分為三類：一、權利金收入，來自植入／侵入式高階醫材表面處理技術授權；二、技術服務收入，包含醫材表面處理服務、醫用塗料、人工水晶體植入系統代工；三、醫材及射出成型等銷售收入，包含人工水晶體、人工水晶體植入系統、醫材表面檢測設備、電漿處理設備、醫材與電子塑膠射出成型產品。2025年度合併收入為新台幣1,130,986千元，產品／服務別為技術服務收入211,173千元（約18.7%）、權利金收入226,139千元（約20.0%）、醫材及射出成型等銷售收入693,674千元（約61.3%）；相較2024年度醫材及射出成型等銷售收入434,353千元，銷售型收入明顯提高。地區別收入依客戶所在地，2025年度美國333,837千元、台灣221,045千元、其他地區309,767千元、西班牙94,551千元、德國82,568千元、英國41,380千元、日本32,726千元、大陸15,112千元，顯示歐美與海外市場為主。公司主要客戶集中度高，2025年度單一A公司收入230,224千元、占20%；公司財報未揭露A公司名稱，MoneyDJ資料指第一代PVP潤滑塗佈技術已獲Alcon採用並為其唯一供應商，因此A公司可能為全球人工水晶體大廠，但此處不將其視為公司正式揭露。公司人工水晶體品牌與產品線包括台灣aspicio、全球與歐洲市場Asqelio、中國大陸推見、併購後的MBI品牌；人工水晶體產品涵蓋單焦點、延伸景深、三焦點、進階單焦點延伸景深及其散光矯正型（Toric）延伸，植入器品牌／系統包括pioli、bioli、lioli、BL-Cart、Cart-D及中國市場推特等。商業模式包含自有品牌醫材銷售、經銷／子公司市場拓展、塗層授權權利金、客製化技術服務與代工。終端應用為白內障與屈光相關眼科手術，終端使用者為眼科醫師、醫院、診所及患者。

Outlook 2025–2028

2025至2028年主要成長動能來自醫材銷售占比提高、歐洲MDR轉換與產品認證、中國大陸註冊與省份經銷推進、併購MBI與詠豪科技後的產品線及供應鏈整合、歐洲與中東市場擴張、高階人工水晶體滲透率提升。2025年公司已呈現醫材及射出成型銷售收入大幅提升，全年營收達11.31億元，年增約31.5%；2026年第1季營收298,615千元，約與2025年第1季297,649千元持平，基本EPS為0.81元，低於2025年第1季1.01元。2025年法說摘要指出，AST VisionCare於2025年7月通過歐盟MDR認證，MDR產品線先完成單焦點人工水晶體認證，高階延伸焦點與三焦點產品仍在審查；公司亦深耕西班牙、沙烏地阿拉伯、越南並拓展德國、法國、荷蘭、波蘭、捷克、瑞士等西歐與北歐市場。中國大陸市場方面，碩創上海已取得植入系統與人工水晶體相關NMPA註冊／生產許可，後續仍須透過各省掛網、集採與經銷合約落地，放量時間具不確定性。產業趨勢上，白內障手術需求受高齡化支撐，散光矯正型人工水晶體與高階人工水晶體滲透率提升有利ASP，法說摘要提及散光矯正型滲透率有望由約10%逐步提升至25%至30%，高階人工水晶體滲透率由約20%至25%朝40%甚至2030年前後50%發展；此為市場展望與公司法說摘要，非保證預測。主要風險包括：一、醫材法規審查與MDR／NMPA／各國上市後臨床要求延遲；二、集團中國大陸事業仍虧損，2025年大陸地區部門稅後損失140,542千元；三、單一大客戶／授權客戶集中，2025年度A公司占營收20%；四、匯率風險，2025年度合併財報揭露美元貨幣性資產較大，匯兌損失18,668千元；五、併購MBI、詠豪後的整合、商譽減損與品質系統風險；六、全球人工水晶體市場由Alcon、J&J Vision、Bausch + Lomb、Hoya、Carl Zeiss Meditec等大廠主導，通路與品牌競爭強；七、研發與臨床試驗費用可能壓抑短期獲利。

Supply Chain

Upstream
  • 疏水性丙烯酸酯等人工水晶體化學原料供應商（公司未揭露具名供應商） 人工水晶體主要成分為疏水性丙烯酸酯等化學材料；公司公開資料未確認具名上游供應商，故不填台股代號。
  • 聚丙烯等植入器塑膠材料供應商（公司未揭露具名供應商） 人工水晶體植入器與植入匣等產品使用聚丙烯等材料；未查得公司正式揭露特定台股供應商。
  • 詠豪科技股份有限公司 台灣未上市公司，奈米醫材持股60%並納入合併；提供醫材及電子塑膠製品射出成型、模具設計開發與生產，強化植入器與機構件供應鏈。
  • Millennium Biomedical, Inc. 美國未上市公司，奈米醫材集團於2024年透過AST VisionCare收購主要股權；具人工水晶體製造與產品線，提供美國製造與既有產品／通路資源。
  • AST Products, Inc. 美國未上市子公司，核心為植／侵入式高階醫材表面處理技術、塗層、設備與技術服務，是集團塗層與授權業務核心。
Downstream
  • A公司（公司財報匿名揭露；二手資料指可能為Alcon） 2025年度占合併營收20%的主要客戶；公司財報僅揭露為A公司，MoneyDJ指出Alcon採用奈米醫材第一代PVP潤滑塗佈技術並為唯一供應商。Alcon為海外上市公司，非台股。
  • 眼科醫院、眼科診所與白內障手術醫師 人工水晶體與植入系統的終端使用通路與臨床決策者，產品用於白內障及屈光相關手術。
  • AST VisionCare Inc.及歐洲子公司／合資通路 美國與歐洲市場經銷與市場拓展平台；法說摘要指出西班牙、德國、法國等市場子公司或合資公司負責經銷網絡建置與品牌推廣，均非台股掛牌公司。
  • 碩創（上海）醫療器械有限公司及中國各省經銷商 大陸子公司與經銷網絡負責中國市場人工水晶體與植入系統銷售；產品取得註冊後仍需省份掛網、集採與經銷合約推進。
  • 中東、越南、歐洲等區域醫材經銷商 法說摘要指出沙烏地阿拉伯、越南、西班牙及西歐／北歐新市場為公司拓展重點；多為海外經銷或醫療通路，非台股掛牌。

Competitors

  • Alcon Inc. 瑞士／美國上市公司，全球人工水晶體與眼科手術設備龍頭之一；同時可能是奈米醫材塗層授權／技術服務重要客戶，非台股掛牌。
  • Johnson & Johnson Vision Johnson & Johnson旗下眼科醫材事業，全球人工水晶體主要競爭者；母公司為美國上市公司，非台股掛牌。
  • Bausch + Lomb 全球眼科醫材與人工水晶體供應商，美國／加拿大上市公司，非台股掛牌。
  • Hoya Surgical Optics 日本HOYA集團旗下人工水晶體與眼科手術產品競爭者；母公司日本上市，非台股掛牌。
  • Carl Zeiss Meditec AG 德國上市眼科醫療科技公司，人工水晶體與眼科手術設備大廠，非台股掛牌。
  • DSM Biomedical 醫材塗層與生醫材料供應商，屬全球醫材塗層競爭者；非台股掛牌。
  • Hydomer, Inc. 美國醫材塗層與材料公司，為醫材塗層領域競爭者；非台股掛牌。
  • Biocoat, Inc. 美國親水性醫材塗層與塗層服務公司，為醫材表面處理競爭者；非台股掛牌。
Sources（15）

This company profile is compiled from public sources (annual reports, filings, news and analyst reports), not finlab backtest data; the 2025–2028 outlook contains forward-looking estimates and is for reference only.

Method and limitations

  • All returns use adjusted close (etl:adj_close), already adjusted for dividends and splits.
  • Excess return is measured against the TAIEX total-return index (dividends included).
  • Valuation regime and percentile stats use an expanding own-history window (no future data).
  • Revenue-signal event dates align to the first trading day after the filing deadline, avoiding look-ahead.
  • Event samples may overlap in time; stats describe historical distribution only and are less reliable when samples are few.

This page is historical statistics for educational purposes and is not investment advice. Investing involves risk; past performance does not indicate future results. Assess and bear the risk yourself before trading.